{"groups":[{"description":"Nivolumab:\n\n* Cycles 1 through 4: 240 mg IV Days 1, 15 of each 28-day cycle.\n* Cycles 5 and beyond: 480 mg IV Day 1 of each 28-day cycle.\n\nPomalidomide:\n\n\\- 4 mg PO QD Days 1-21 of each 28-day cycle.\n\nDexamethasone:\n\n* Participants \\</= 75 years old: 40 mg PO Days (1, 8, 15, and 22) of each cycle\n* Participants \\> 75 years old: 20 mg PO Days (1, 8, 15, and 22) of each cycle.","id":"FG000","title":"Arm A: N-Pd"},{"description":"Pomalidomide:\n\n\\- 4 mg PO QD Days 1-21 of each 28-day cycle.\n\nDexamethasone:\n\n* Participants \\</= 75 years old: 40 mg PO Days (1, 8, 15, and 22) of each cycle\n* Participants \\> 75 years old: 20 mg PO Days (1, 8, 15, and 22) of each cycle.","id":"FG001","title":"Arm B: Pd"},{"description":"Nivolumab:\n\n* Cycles 1 through 4: 240 mg IV Days 1, 15 of each 28-day cycle.\n* Cycles 5 and beyond: 480 mg IV Day 1 of each 28-day cycle.\n\nElotuzumab:\n\n* Cycles 1 - 2: 10 mg/kg IV Days 1, 8, 15, and 22 of each 28-day cycle.\n* Cycle 3 and 4: 10mg/kg IV Day 1 and 15 of each 28-day cycle.\n* Cycles 5 and beyond: 20 mg/kg IV Day 1 of each 28-day cycle.\n\nPomalidomide:\n\n4 mg PO QD Days 1-21 of each 28-day cycle.\n\nDexamethasone:\n\nDays 1, 8, 15, and 22 of each cycle.\n\n* Participants \\</= 75 years old: weeks with elotuzumab dosing: 28 mg PO + 8 mg IV and 40 mg PO on non-elotuzumab dosing weeks.\n* Participants \\> 75 years old: weeks with elotuzumab dosing: 8 mg PO + 8 mg IV and 20 mg PO on non-elotuzumab dosing weeks.","id":"FG002","title":"Arm C: NE-Pd"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"0"}],"type":"Participant request to discontinue study treatment"},{"reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"}],"type":"Administrative reason by sponsor"},{"reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"}],"type":"Participant no longer meets study criteria"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"75"},{"groupId":"FG001","numSubjects":"71"},{"groupId":"FG002","numSubjects":"24"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"72"},{"groupId":"FG001","numSubjects":"70"},{"groupId":"FG002","numSubjects":"24"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"0"}],"type":"NOT COMPLETED"}],"title":"Pre-Treatment Period"},{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"47"},{"groupId":"FG001","numSubjects":"50"},{"groupId":"FG002","numSubjects":"16"}],"type":"Disease progression"},{"reasons":[{"groupId":"FG000","numSubjects":"9"},{"groupId":"FG001","numSubjects":"8"},{"groupId":"FG002","numSubjects":"2"}],"type":"Other reasons"},{"reasons":[{"groupId":"FG000","numSubjects":"6"},{"groupId":"FG001","numSubjects":"3"},{"groupId":"FG002","numSubjects":"2"}],"type":"Study drug toxicity"},{"reasons":[{"groupId":"FG000","numSubjects":"4"},{"groupId":"FG001","numSubjects":"4"},{"groupId":"FG002","numSubjects":"2"}],"type":"Adverse event unrelated to study drug"},{"reasons":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"1"}],"type":"Participant withdrew consent"},{"reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"1"}],"type":"Participant request to discontinue study treatment"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"2"},{"groupId":"FG002","numSubjects":"0"}],"type":"Maximum clinical benefit"},{"reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"}],"type":"Death"},{"reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"}],"type":"Poor/non-compliance"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"0"}],"type":"Participant no longer meets study criteria"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"72"},{"groupId":"FG001","numSubjects":"70"},{"groupId":"FG002","numSubjects":"24"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"8"},{"groupId":"FG002","numSubjects":"0"}],"type":"NE-Pd Crossover"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"}],"comment":"Completed treatment","type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"72"},{"groupId":"FG001","numSubjects":"70"},{"groupId":"FG002","numSubjects":"24"}],"type":"NOT COMPLETED"}],"title":"Treatment Period"}],"preAssignmentDetails":"This study contains an exploratory third arm evaluating the clinical benefit and the safety of the combination therapy of elotuzumab, nivolumab, pomalidomide and dexamethasone (Arm C: NE-Pd). Participants randomized to the Pd arm were allowed to cross over to this exploratory NE-Pd arm at the time of progression."}